The massive near-expiration exercise wave suggests the stock traded above the $2.50 warrant price throughout Q3 2026, which is consistent with a $463M market cap. With the warrant overhang now largely extinguished (only ~1.8M warrants unexercised), the primary equity overhang is removed. Monitor upcoming Q3 2026 financials for the cash balance impact and any forward guidance on pipeline spending.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 14 $2.91entry
- T+1 · 2mo ago −10.82%α −10.37% · $2.60
- T+5 · 8w ago −15.46%α −15.57% · $2.46
- T+20 · 5w ago −38.49%α −40.75% · $1.79
- T+45 · todayOpen
- T+60 · in 21d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cabaletta Bio reports that warrants issued in a June 2025 public offering expired on September 12, 2026, and that 97% (46.0M of 53.1M) were exercised in the three months before expiration, generating $115M in aggregate gross proceeds in Q3 2026 and ~$128.2M total since issuance. The filing is a routine update on warrant exercise activity and contains no new operational or pipeline developments.
Key Facts
- 53,090,190 common stock warrants were issued in June 2025 with a $2.50 exercise price and an expiration date of September 12, 2026.
- 5,275,100 warrants were exercised from issuance through June 30, 2026, generating ~$13.2M in gross proceeds.
- 46,011,900 warrants were exercised from July 1, 2026 through the expiration date, generating ~$115.0M in aggregate gross proceeds.
- Total aggregate gross proceeds from all warrant exercises: approximately $128.2 million.
Financial Impact
Cabaletta received approximately $128.2 million in gross proceeds from warrant exercises, including ~$115.0M in the last ~2.5 months before expiration.
Risk Factors
- Dilution from the remaining ~1.8M warrants that were not exercised is minimal.
- The ~$128M cash infusion could pressure management to show progress on pipeline catalysts to justify the stock's valuation.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001759138-26-000041 |
| Document: 0001759138-26-000041-index-headers.html | 0001759138-26-000041 |
| Document: 0001759138-26-000041-index.html | 0001759138-26-000041 |
| Document: 0001759138-26-000041.txt | 0001759138-26-000041 |
Track record
29 reports on CABA
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers